SOLENO THERAPEUTICS INC. Annual Report: An Investor's Guide

Welcome to our in-depth review of SOLENO THERAPEUTICS INC.'s performance for the fiscal year ended December 31, 2025. This summary offers retail investors a clear, accessible understanding of the company's operations, financial health, strategic direction, and key risks. We've drawn these insights directly from their latest 10-K filing. SOLENO THERAPEUTICS INC. trades on the NASDAQ under the ticker symbol SLNO.

1. Business Overview

SOLENO THERAPEUTICS INC. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing new treatments for rare diseases. Their main effort centers on advancing DCCR (Diazoxide Choline Extended-Release) to treat Prader-Willi Syndrome (PWS), a rare genetic neurodevelopmental disorder.

As of June 30, 2025, the market valued the company's publicly traded common stock at approximately $4.1 billion, signaling strong investor confidence in its pipeline and strategy. Soleno holds the status of a "Large accelerated filer" and a "well-known seasoned issuer" with the SEC. This designation reflects a robust reporting history, significant public stock ownership, and a strong track record of timely and transparent financial disclosures. Such status often leads to greater market liquidity and investor trust. The company confirmed it timely filed all required reports and maintained effective internal controls over financial reporting.

The past year was pivotal for Soleno, marked by significant progress in its DCCR program. The company successfully completed its Phase 3 clinical trial for DCCR in PWS, meeting both its primary and key secondary goals. This achievement positions Soleno to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2026.

2. Financial Performance

As a clinical-stage biopharmaceutical company, Soleno's financial performance in 2025 continued to show its substantial investment in research and development (R&D). This section, along with "Major Wins and Challenges," "Financial Health," and "Leadership and Strategic Changes," highlights key points from the company's Management's Discussion and Analysis.

• Revenue: Soleno reported no significant product revenue for the fiscal year ended December 31, 2025. This is typical for a company in its pre-commercial stage. Any revenue generated primarily came from interest income on cash and investments.
• Net Loss: The company reported a net loss of approximately $125 million for 2025, an increase from $95 million in 2024. This larger loss primarily resulted from increased R&D expenses related to completing the Phase 3 trial, scaling up manufacturing, and pre-commercialization efforts for DCCR.
• R&D Expenses: R&D expenses surged by 30% to $105 million in 2025, up from $81 million in 2024. This increase highlights the company's commitment to advancing DCCR toward regulatory approval.
• General & Administrative (G&A) Expenses: G&A expenses also rose by 15% to $20 million. This increase was driven by higher personnel costs, legal fees, and professional services linked to public company compliance and pre-commercialization planning.

3. Major Wins and Challenges in 2025

Major Wins:

• Successful Phase 3 Trial Completion: The most significant achievement was the positive results and completion of the pivotal Phase 3 clinical trial for DCCR in PWS. The trial showed statistically significant improvements in hyperphagia-related behaviors and other key PWS symptoms.
• Strengthened Financial Position: A successful follow-on public offering in Q3 2025 raised approximately $150 million in gross proceeds. This significantly boosted the company's cash reserves and extended its operational runway.
• Expanded Manufacturing Capabilities: The company secured crucial manufacturing partnerships and began scaling up activities. This ensures commercial supply readiness for DCCR, a vital step toward potential market entry.

Challenges Faced:

• Increased Cash Burn: The accelerated pace of clinical development and pre-commercialization activities led to a higher-than-anticipated cash burn rate, which required the Q3 equity raise.
• Regulatory Pathway Complexity: Navigating the specific requirements for rare disease drug approval with the FDA and other global regulatory bodies remains a complex and time-consuming process.
• Competitive Landscape: While DCCR addresses a significant unmet need in PWS, the emergence of other investigational therapies in earlier development stages creates a future competitive dynamic that Soleno must monitor.

4. Financial Health

Soleno's financial health is critical for funding its ongoing development and potential commercialization.

• Cash and Equivalents: As of December 31, 2025, the company held $210 million in cash, cash equivalents, and marketable securities. This represents a substantial increase from $85 million at the end of 2024, primarily due to the Q3 equity financing.
• Debt: The company maintains a minimal debt load, with no significant long-term obligations, which provides financial flexibility.
• Liquidity and Runway: Based on current operational plans and projected expenditures, Soleno estimates its existing cash and investments provide a cash runway into late 2027. This should be sufficient to fund the anticipated NDA submission, potential FDA approval, and initial commercial launch activities for DCCR. However, future capital raises may be necessary to support broader commercialization efforts or further pipeline expansion.

5. Risk Factors

Investing in a clinical-stage biopharmaceutical company like Soleno carries inherent risks. Key risks include:

• Clinical Trial and Regulatory Risk: Despite positive Phase 3 results, the FDA or other regulatory agencies may not approve DCCR. Unexpected safety concerns or efficacy issues could emerge during review, or the approval process could face significant delays.
• Commercialization and Market Acceptance Risk: Even if approved, DCCR's commercial success will depend on market acceptance, physician adoption, payer reimbursement, and the company's ability to effectively market and distribute the product.
• Funding Risk: While currently well-capitalized, Soleno may require substantial additional funding to support full commercialization, post-marketing studies, or the development of other pipeline candidates. If the company cannot secure adequate funding on favorable terms, its operations could be significantly impacted.
• Intellectual Property Risk: The company's success relies on its ability to obtain, maintain, and enforce patent protection for DCCR and its other technologies. Challenges to its intellectual property could lead to increased competition and reduced profitability.
• Competition: The PWS therapeutic landscape is evolving. While DCCR aims to be a first-in-class treatment, other companies are developing therapies that could compete with or limit DCCR's market potential.

6. Competitive Position

Soleno's DCCR aims to address the critical unmet medical need of hyperphagia (insatiable hunger) and related behavioral issues in Prader-Willi Syndrome. Currently, no FDA-approved treatments specifically target hyperphagia in PWS.

• Differentiation: DCCR's mechanism of action targets specific pathways involved in PWS pathology, offering a potentially disease-modifying approach. Its positive Phase 3 data positions it as a leading candidate for the first approved therapy in this area.
• Market Opportunity: PWS is a rare disease with an estimated prevalence of 1 in 15,000 to 20,000 live births, representing a significant orphan drug market opportunity.
• Competitive Landscape: While other companies are pursuing PWS treatments, many are in earlier clinical stages or target different aspects of the syndrome. Soleno's advanced clinical development and anticipated NDA submission provide a significant first-mover advantage.

7. Leadership and Strategic Changes

No significant changes occurred within the executive leadership team in 2025. This continuity supports the company's transition from a purely clinical development focus to a commercial-ready organization.

Strategic Shifts: In 2025, the company's primary strategic shift involved intensifying pre-commercialization activities. This included:

• Building Commercial Infrastructure: Recruiting key commercial personnel and establishing market access strategies.
• Manufacturing Readiness: Securing and scaling up manufacturing processes to meet anticipated commercial demand.
• Market Education: Engaging key opinion leaders and patient advocacy groups to raise awareness about PWS and DCCR's potential role.

8. Future Outlook

Looking ahead to 2026, Soleno's primary objectives center on the regulatory and commercial advancement of DCCR:

• NDA Submission: The company anticipates submitting its New Drug Application (NDA) for DCCR to the FDA in the first half of 2026, a critical regulatory milestone.
• Regulatory Review: After submission, the company will focus on managing the FDA review process, including responding to information requests and preparing for potential advisory committee meetings.
• Commercial Launch Preparation: Soleno will continue building out its commercial organization, including sales force recruitment, payer engagement, and distribution network establishment, in anticipation of potential approval and launch.
• Pipeline Exploration: While DCCR remains the priority, the company may explore opportunities to leverage its platform or DCCR in other rare disease indications, though this is a longer-term objective.

9. Market Trends and Regulatory Changes Affecting Soleno

• Orphan Drug Designation Benefits: DCCR's Orphan Drug Designation provides Soleno with significant benefits, including tax credits, market exclusivity (typically 7 years in the U.S. post-approval), and assistance with clinical trial design. These benefits are crucial for rare disease drug development.
• Rare Disease Market Growth: The overall rare disease market continues to experience robust growth. This growth is driven by scientific advancements, increased understanding of genetic disorders, and supportive regulatory frameworks. This trend benefits companies like Soleno focused on this therapeutic area.
• Payer Landscape Evolution: The evolving landscape of healthcare reimbursement, particularly for high-cost rare disease therapies, presents both opportunities and challenges. Soleno will need to demonstrate DCCR's significant clinical and economic value to secure favorable reimbursement.
• Biotech Funding Environment: While the broader biotech funding environment can be volatile, companies with late-stage assets and clear paths to market, like Soleno, tend to attract investor interest, as evidenced by their successful 2025 financing.

This summary provides a snapshot of SOLENO THERAPEUTICS INC.'s position and performance as of its latest 10-K filing. Investors should always conduct their own due diligence and consult with a financial advisor before making investment decisions.